

**MHRA dispensation on movement of QIV:** We have received the following information from NHSE national team regarding movement of QIV stocks. The same rules as currently apply to aTIV are being extended to QIV for where there are shortages.

As the vaccination season moves into its later stages, with an increasing number of people already having had their jab, we are aware that some practices may have surplus stock of the quadrivalent influenza vaccine QIV, while others - that have had higher than anticipated demand for vaccination - may need additional supplies to those ordered. Whilst the majority of providers have adequate supplies of quadrivalent influenza vaccine (QIV), as a precautionary and practical measure at this stage in the vaccine programme, to support those providers whose uptake has exceeded their order volume, the MHRA has agreed that the same dispensation as agreed for adjuvanted trivalent influenza vaccine (aTIV), can be applied to QIV.

The Medicines and Healthcare Products Regulatory Agency (MHRA) has a role in regulating medicines supply. Normally, medication can only be passed between providers where a wholesaler licence exists, however the MHRA has confirmed that with regards to the QIV, recommended for those aged under 65 and in a clinical risk group, it would not prevent supply under the given circumstances of “in short supply” or “no supply” available provided that: the surgery that is holding the excess stock can give an assurance that the vaccine has been held properly in the correct temperature controlled conditions;

1. confirmed record keeping of temperature monitoring is available;
2. the surgery that requests the QIV is able to verify the assurances given;
3. the vaccine can be transported appropriately under the right conditions.